Better-than-expected price data can’t quite blunt worries about consumers pulling back, as companies keep scrambling to ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug ...

Bearish flow noted in Novo Nordisk (NVO) with 7,917 puts trading, or 1.2x expected. Most active are 3/14 weekly 76 puts and Sep-25 110 puts, ...

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday. The company's stock lost 8.9% as of 10:10 a.m. ET and was down as much as 9.2% earlier in the day. The drop comes as the S&P 500 ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Shares of Novo Nordisk and Eli Lilly slipped in premarket trading Wednesday after Roche said it had landed a $5.3 billion ...

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...